Document ID: chunk:federal_register_of_legislation:F2023C01042:reg:9:p3
Version: federal_register_of_legislation:F2023C01042
Segment Type: reg
Provision Reference: reg 9 (pt 3/5)
Character Range: 12309–15581

secondary parkinsonism; or
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(z)          having a paraneoplastic encephalomyelitis at the time of the clinical onset of secondary parkinsonism;
(3)          having an episode of acute cholinergic poisoning from exposure to an organophosphorus ester within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: acute cholinergic poisoning and organophosphorus ester are defined in the Schedule 1 - Dictionary.
(4)          having moderate to severe traumatic brain injury within the six months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(5)          having an intracranial space occupying lesion within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(6)          having hydrocephalus, or draining of hydrocephalus, within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: hydrocephalus is defined in the Schedule 1 - Dictionary.
(7)          having a cerebrovascular accident, excluding transient ischaemic attack, within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(8)          having a disease from the specified list of diseases involving the cerebral vessels, in the presence of neuroimaging findings of brain stem or cerebral white matter lesions, haemorrhage or infarction, at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: specified list of diseases involving the cerebral vessels is defined in the Schedule 1 - Dictionary.
(9)          having a subarachnoid haemorrhage within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(10)      having an acquired cerebrovascular malformation or dural arteriovenous fistula at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
(11)      having an hypoxic cerebral insult within the one year before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: hypoxic cerebral insult is defined in the Schedule 1 - Dictionary.
(12)      having encephalitis within the six weeks before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: encephalitis is defined in the Schedule 1 - Dictionary.
(13)      being infected with the human immunodeficiency virus before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(14)      having neurosyphilis at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: neurosyphilis is defined in the Schedule 1 - Dictionary.
(15)      having neurocysticercosis at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
(16)      inhaling carbon disulphide vapour in an enclosed space, or having cutaneous contact with carbon disulphide, for a cumulative period of at least 500 hours, within the ten years before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(17)      inhaling or ingesting methanol or ethylene glycol, and having clinical, haematological or biochemical evidence of methanol